Skip to main content
OpenTrials
Completed

NCT Number: NCT02883985

Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers

The purpose of this study is to determine whether high dose of radiation therapy (RT) are effective over standard 6-week radiation treatment in patients with breast cancer

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

NYU Perlmutter Cancer Center

New York, 10016, United States

About this study

Hypo-fractionation (several large fractions as the only radiation treatment) for breast cancer irradiation was common in the forties and 50s and, while very successful in achieving tumor control, was found to leave significantly inferior cosmetic results due to severe fibrosis and telangiectasia compared to those obtained with multiple fraction regimens (38-40). These complications were due to the use of very large fields, with the inclusion of a large proportion of uninvolved skin and tissue surrounding the tumor.

Based on these assumptions, a few large fractions can be safely delivered to breast cancers provided that 1) the target volume is sufficiently small and 2) the radiation technique assures maximum sparing of the surrounding normal tissue. Conformal RT to the tumor bed of T1 breast cancers satisfies both requirements.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Post-menopausal women (at least 2 years without menstrual period):

hysterectomized patients need follicle-stimulating hormone (FSH) confirmation of post-menopausal status.

  • Original tumor non-palpable (mammographically detected).
  • Small primary tumor (pT1) breast cancer, excised with negative margins (defined as at least a 5 mm margin).
  • N0 or sentinel node negative or N0 clinically if the tumor is <1 cm in size.
  • Patient offered six weeks of post-segmental mastectomy conventional radiation therapy and declined.
  • Prescribed antihormonal therapy as part of their management.

Exclusion criteria

  • Previous radiation therapy to the ipsilateral breast.
  • Presence of a proportion of ductal carcinoma in situ (DCIS) in the pathology specimen which is compatible with extensive intraductal component (EIC).
  • Women incapable of providing their own consent. Mental status will be assessed by the Principal Investigator using the Radiation Therapy Oncology Group (RTOG) Mini-Mental Status Examination.
  • Women with a diagnosis of multifocal breast cancer.

Treatment and study plan

6 Gy/ fraction

Radiation

All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.

In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment.

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: Up to 5 years

Secondary outcomes

  1. TGF-beta 1 determinations

    Time frame: From baseline to up to 4 weeks

    Blood specimens will be collected by venipuncture, before starting treatment, immediately after the last treatment fraction

  2. Ultrasound for target localization

    Time frame: up to 4 weeks

    Ultrasound is ideal for imaging soft tissues unobstructed by bone and has been used successfully in conjunction with the treatment of prostate cancer to verify compliance between the daily location of the prostate and the planned location with respect to the treatment linear accelerator. By using ultrasound to image the post-operative tumor bed of the breast in "real-time", the operator may automatically align the tumor bed with treatment machine on each day of treatment

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Registry information

Official study title

Hypo-Fractionated Conformal Radiation Therapy to the Tumor Bed After Segmental Mastectomy

Important dates

Study start
2000
Primary completion
2007
Study completion
2017
First posted
Aug 30, 2016
Registry last updated
Dec 21, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.